Dosing related effects of zoledronic acid on bone markers and creatinine clearance in patients with multiple myeloma and metastatic breast cancer

Acta Oncologica

Volumn 53, Issue 4, 2014, Pages 547-556

  Søe, Kent ^a   Delaissé, Jean Marie ^a   Jakobsen, Erik H ^a   Hansen, Charlotte T ^b   Plesner, Torben ^a  

^a LILLEBAELT HOSPITAL   (Denmark)

^b ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; CARBOXY TERMINAL TELOPEPTIDE; COLLAGEN TYPE 1; ZOLEDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT; CREATININE; IMIDAZOLE DERIVATIVE; TUMOR MARKER;

ADULT; AGED; ARTICLE; BONE DISEASE; BREAST CANCER; COHORT ANALYSIS; CONTROLLED STUDY; CREATININE CLEARANCE; DRUG EFFECT; FEMALE; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; BONE NEOPLASMS; BREAST NEOPLASMS; CANCER STAGING; CLINICAL TRIAL; DOSE RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FOLLOW UP; METABOLISM; PATHOLOGY; PROGNOSIS; RADIOIMMUNOASSAY; SECONDARY; URINE;

ADULT; BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; BREAST NEOPLASMS; CREATININE; DIPHOSPHONATES; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMIDAZOLES; MALE; MIDDLE AGED; MULTIPLE MYELOMA; NEOPLASM STAGING; PROGNOSIS; PROSPECTIVE STUDIES; RADIOIMMUNOASSAY; TUMOR MARKERS, BIOLOGICAL;

EID: 84896948239     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.3109/0284186X.2013.844358     Document Type: Article

References (25)

1. Coleman R, Gnant M, Morgan G, Clezardin P. Effects of bone-targeted agents on cancer progression and mortality. J Natl Cancer Inst 2012; 104: 1059-67.
2. Morgan GJ, Davies FE, Gregory WM, Cocks K, Bell SE, Szubert AJ, et al. First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): A randomised controlled trial. Lancet 2011 ; 376: 1989-99.
3. Yan T, Yin W, Zhou Q, Zhou L, Jiang Y, Du Y, et al. The efficacy of zoledronic acid in breast cancer adjuvant therapy: A meta-analysis of randomised controlled trials. Eur J Cancer 2012 ; 48: 187-95.
4. Aapro M, Abrahamsson PA, Body JJ, Coleman RE, Colomer R, Costa L, et al. Guidance on the use of bisphosphonates in solid tumours: Recommendations of an international expert panel. Ann Oncol 2008; 19: 420-32.
5. Guise TA, Brufsky A, Coleman RE. Understanding and optimizing bone health in breast cancer. Curr Med Res Opin 2010; 26(Suppl 3): 3-20.
6. Lund T, Abildgaard N, Delaisse JM, Plesner T. Effect of withdrawal of zoledronic acid treatment on bone remodelling markers in multiple myeloma. Br J Haematol 2010; 151: 92-3.
7. Richardson PG, Laubach JP, Schlossman RL, Ghobrial IM, Mitsiades CS, Rosenblatt J, et al. The Medical Research Council Myeloma IX trial: The impact on treatment paradigms. Eur J Haematol 2012; 88: 1-7.
8. Terpos E, Sezer O, Croucher PI, Garcia-Sanz R, Boccadoro M, San Miguel J, et al. The use of bisphospho-nates in multiple myeloma: Recommendations of an expert panel on behalf of the European Myeloma Network. Ann Oncol 2009; 20: 1303-17.
9. Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008; 111: 2516-20.
10. Chia SK, Speers CH, D'yachkova Y, Kang A, Malfair-Taylor S, Barnett J, et al. The impact of new chemotherapeutic and hormone agents on survival in a population-based cohort of women with metastatic breast cancer. Cancer 2007; 110: 973-9.
11. Giordano SH, Buzdar AU, Smith TL, Kau SW, Yang Y, Hortobagyi GN. Is breast cancer survival improving? Cancer 2004; 100: 44-52.
12. Abrahamsen B. Bone freezing and bisphosphonates. Maturitas 2011; 69: 1-2.
13. Odvina CV, Zerwekh JE, Rao DS, Maalouf N, Gottschalk FA, Pak CYC. Severely suppressed bone turnover: A potential complication of Alendronate Therapy. J Clin Endocrinol Metab 2005; 90: 1294-301.
14. Soe K, Plesner T, Jakobsen EH, Hansen CT, Jorgensen HB, Delaisse JM. Is retention of zoledronic acid onto bone different in multiple myeloma and breast cancer patients with bone metastasis? J Bone Miner Res 2013; 28: 1738-50.
15. Rajkumar SV, Harousseau JL, Durie B, Anderson KC, Dimopoulos M, Kyle R, et al. Consensus recommendations for the uniform reporting of clinical trials: Report of the International Myeloma Workshop Consensus Panel 1. Blood 2011; 117: 4691-5.
16. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000; 92: 205-16.
17. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41.
18. Hadji P. Managing bone health with zoledronic acid: A review of randomized clinical study results. Climacteric 2011; 14: 321-32.
19. Hadji P, Gnant M, Aapro M, Lipton A, Coleman R. Dosing of zoledronic acid throughout the treatment continuum in breast cancer. Crit Rev Oncol Hematol 2011; 79: 175-88.
20. Lund T, Abildgaard N, Andersen TL, Delaisse JM, Plesner T. Multiple myeloma: Changes in serum C-terminal telopep-tide of collagen type I and bone-specific alkaline phosphatase can be used in daily practice to detect imminent osteolysis. Eur J Haematol 2010; 84: 412-20.
21. Hauge EM, Qvesel D, Eriksen EF, Mosekilde L, Melsen F. Cancellous bone remodeling occurs in specialized compartments lined by cells expressing osteoblastic markers. J Bone Miner Res 2001; 16: 1575-82.
22. Andersen TL, Sondergaard TE, Skorzynska KE, Gnaes-Hansen F, Plesner TL, Hauge EM, et al. A physical mechanism for coupling bone resorption and formation in adult human bone. Am J Pathol 2009; 174: 239-47.
23. Andersen TL, Soe K, Sondergaard TE, Plesner T, Delaisse JM. Myeloma cell-induced disruption of bone remodelling compartments leads to osteolytic lesions and generation of osteoclast-myeloma hybrid cells. Br J Haematol 2010; 148: 551-61.
24. Oh WK, Proctor K, Nakabayashi M, Evan C, Tormey LK, Daskivich T, et al. The risk of renal impairment in hormone-refractory prostate cancer patients with bone metastases treated with zoledronic acid. Cancer 2007; 109: 1090-6.
25. Weide R, Koppler H, Antras L, Smith M, Chang MP, Green J et al. Renal toxicity in patients with multiple myeloma receiving zoledronic acid vs. Ibandronate: A retrospective medical records review. J Cancer Res Ther 2010; 6: 31-5.